TerminatedNot applicableNCT03020797

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stony Brook University
Principal Investigator
Nurcan Gursoy, MD
Stony Brook Medicine Dept. of Neurology
Intervention
Perampanel(drug)
Enrollment
12 enrolled
Eligibility
18-80 years · All sexes
Timeline
20172023

Study locations (1)

Collaborators

Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03020797 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials